Source: International Congress 2016 – New and old therapies for chronic lung diseases
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Dariusz Gawryluk (Warsaw, Poland), Dariusz Gawryluk, Justyna Fijolek, Elzbieta Wiatr. Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA). Eur Respir J 2016; 48: Suppl. 60, 1769

Member's Comments

No comment yet.

Related content which might interest you: Long-term outcomes of rituximab (RTX) therapy in recurrent Granulomatosis with Polyangiitis (GPA) Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon Year: 2018 Granulomatosis with polyangiitis (Wegener&s) Source: Eur Respir Mon 2011; 54: 1-14 Year: 2011 Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019 Year: 2020 Secondary organizing pneumonia (BOOP)-associated with granulomatosis with polyangiitis [Wegener granulomatosis (WG)]: A clinicoradiological study of 19 cases Source: International Congress 2014 – ILDs 6 Year: 2014 Asthma follow-up and treatment in a group of 28 patients with eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002 ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020 Year: 2020 Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab Source: Eur Respir J 2006; 27: 644-646 Year: 2006 New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Clinical management of orphan lung diseases Year: 2013 The role of intratracheal dilation – Injection technique in treatment of granulomatosis with polyangiitis (GPA) patients with subglottic stenosis Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Physiological characteristics in patients with microscopic polyangitis (MPA) and wegener‘s granulomatosis (WG) Source: Eur Respir J 2004; 24: Suppl. 48, 327s Year: 2004 Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases Year: 2020 Alveolar haemorrhage syndromes Source: Eur Respir Mon 2011; 54: 15-31 Year: 2011 Coexistent granulomatosis with polyangiitis (Wegener‘s) and Crohn disease: A clinicopathologic description of cases Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 An atypical presentation of granulomatosis with polyangiitis (GPA) with pituitary involvement Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Wegener's granulomatosis (WG) - clinical features and response to treatment in 18 cases Source: Eur Respir J 2002; 20: Suppl. 38, 64s Year: 2002